Last reviewed · How we verify
Inhaled Iloprost
At a glance
| Generic name | Inhaled Iloprost |
|---|---|
| Also known as | Ilomedin, Ventavis by Actelion Pharmaceuticals US, Inc., Brand name - Ventavis, Ventavis |
| Sponsor | Heidelberg University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Longitudinal Outcomes of Patients With Group 3 Pulmonary Hypertension Treated With Iloprost
- AIRDROP: Can we Improve Adherence to Inhaled Treatment for Pulmonary Arterial Hypertension? (NA)
- Patient-Reported Outcomes and Adherence After Transition From Inhaled Iloprost to Oral Selexipag in Pulmonary Arterial Hypertension
- Hemodynamic Effects of Inhaled Iloprost in PH-COPD (HOLLYWOOD) (NA)
- Effects of Iloprost on Pulmonary Oxygenation in Obese Patients During One-lung Ventilation (NA)
- Iloprost Power 15 in Pulmonary Arterial Hypertension (PHASE3)
- The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension (PHASE3)
- Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inhaled Iloprost CI brief — competitive landscape report
- Inhaled Iloprost updates RSS · CI watch RSS
- Heidelberg University portfolio CI